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OBJECTIVES We sought to examine the association between aortic valve sclerosis (AVS) and systemic
endothelial manifestations of the atherosclerotic process.
BACKGROUND Clinical and experimental studies suggest that AVS is a manifestation of the atherosclerotic
process. Systemic endothelial dysfunction is an early sign of the atherosclerotic process and
can be assessed by ultrasonography of the brachial artery.
METHODS A total of 102 in-hospital patients (76 men; mean age 63.5  9.7 years) referred to the stress
echocardiography laboratory underwent: 1) transthoracic echocardiography, with specific
assessment of AVS (thickened valve leaflets with a transaortic flow velocity 2.5 m/s); 2)
stress echocardiography; 3) coronary angiography, with evaluation of the Duke score (from 0
[normal] to 100 [most severe disease]); and 4) an endothelial function study, with assessment
of endothelium-dependent, post-ischemic, flow-mediated dilation (FMD).
RESULTS Aortic valve sclerosis was present in 35 patients (group I) and absent in 67 (group II). Groups
I and II were similar in terms of the frequency of stress-induced wall motion abnormalities
(35.3% vs. 19.4%, p  NS) and the angiographic Duke score (33.8  28.6 vs. 35.2  29.1,
pNS). Patients with AVS showed a markedly lower FMD than those without AVS (2.2
3.5% vs. 5.3  5.3%, p  0.01). On multivariate analysis, only FMD was highly predictive
of AVS, with an odds ratio of 1.18 for each percent decrease in FMD (95% confidence
interval 1.05 to 1.32; p  0.01).
CONCLUSIONS Aortic valve stenosis is associated with systemic endothelial dysfunction. This observation
may provide a mechanistic insight into the emerging association between AVS and
cardiovascular events. (J Am Coll Cardiol 2003;41:136–41) © 2003 by the American
College of Cardiology Foundation
Early atherosclerosis involves the endothelium of many
arteries. Vascular dysfunction has been implicated as an
early event in atherogenesis (1). Moreover, vascular dysfunc-
tion associated with vascular injury has been postulated as
the precursor of atherosclerosis (2). Endothelial dysfunction
is thought to be an important factor in the development of
atherosclerosis, hypertension, and heart failure.
Atherosclerosis risk factors (3,4) and clinical atheroscle-
rotic cardiovascular disease (5) are independently associated
with aortic valve sclerosis (AVS), suggesting that AVS
represents an atherosclerosis-like process involving the aor-
tic valve (6). Aortic valve sclerosis in the absence of
obstruction of ventricular outflow affects 21% to 26% of
adults 65 years old (4,7). It appears to have a similar
etiology to that of mitral annular calcification (MAC),
which has a highly significant association with atheroscle-
rosis of the vascular system, including coronary artery
disease (CAD) (8,9).
Over the past decade, a noninvasive technique has
evolved to evaluate flow-mediated dilation (FMD), an
endothelium-dependent function, in the brachial artery
after occlusion (10–13). This stimulus provokes the endo-
thelium to release nitric oxide, with subsequent vasodilation
that can be imaged and quantitated as an index of vasomotor
function (14).
Ultrasound imaging of the brachial artery during re-
active hyperemia is a widely used tool for quantifying
endothelium-dependent vasomotion (15). Impaired
endothelium-dependent vasomotion is a diffuse disease
process resulting in abnormal regulation of blood vessel tone
and loss of several atheroprotective effects of the normal
endothelium (16), and impaired peripheral endothelial
function may also be a marker of increased future cardio-
vascular risk (17).
Initial preliminary clinical and experimental studies sug-
gest that AVS is a manifestation of the atherosclerotic
process (18). Systemic endothelial dysfunction is an early
sign of the atherosclerotic process and can be assessed by
brachial artery ultrasonography. The present study’s hy-
pothesis is that AVS is associated with systemic endothelial
dysfunction. Therefore, we examined the association be-
tween AVS and systemic endothelial manifestations of the
atherosclerotic process in patients with known or suspected
CAD.
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METHODS
Study patients. The study population consisted of 102
hospitalized patients (76 men and 26 women; mean age
63.5  9.7 years) with suspected or known CAD, referred
to the stress echocardiography laboratory and scheduled for
subsequent coronary angiography. Seventy-two patients had
stable angina pectoris, 35 had a previous myocardial infarc-
tion, and 29 had a previous revascularization procedure (13
with coronary angioplasty and 16 with coronary artery
bypass graft surgery). After taking a clinical history, with
special attention to risk factor identification, all patients
underwent, on different days, in a variable sequence, and
within 15 days: 1) complete transthoracic echocardiography
(TTE); 2) stress echocardiography; 3) an endothelial func-
tion study; and 4) coronary angiography. All patients had
stopped nitrate treatment at the time of the endothelial
function study. Each of the four tests was interpreted by
observers who were unaware of the results of the other tests.
Patients with aortic stenosis (transaortic flow velocity
2.5 m/s), rheumatic valvular disease, prosthetic valves,
bicuspid aortic valves, congenital heart disease, bacterial
endocarditis, or hypertrophic obstructive cardiomyopathy,
as well as those on hemodialysis, were excluded from the
study. Patients with a poor acoustic window (n  2) and
acute, unstable coronary syndromes were also excluded.
The hospital’s Institutional Review Board approved the
study, and all patients gave written, informed consent.
Risk factors. The cardiac risk factors considered in this
study were age, gender, family history of CAD, diabetes
mellitus, hypertension, hypercholesterolemia, and history of
smoking. Diabetes was defined as hyperglycemia requiring
previous or ongoing pharmacologic therapy. Hypertension
was defined as either a systolic or diastolic elevation of blood
pressure (140/90 mm Hg) or ongoing antihypertensive
pharmacologic therapy. Hypercholesterolemia was defined
as a total cholesterol level 200 mg/dl or current treatment
with lipid-lowering medication. Current cigarette smoking
was defined as active smoking within the past 12 months.
Transthoracic echocardiography. Complete TTE studies
were performed in all patients, by use of a commercially
available system (Acuson Sequoia C256, Mountain View,
California; Hewlett-Packard SONOS 5500, Andover,
Massachusetts).
We defined AVS as a focal area of increased echogenicity
and thickening of the aortic valve leaflets without restriction
of leaflet motion, with a transaortic flow velocity 2.5 m/s
on TTE, using the criteria of Stewart et al. (4) and Otto et
al. (5).
The TTE criteria for MAC included an intense echo-
producing structure located at the junction of the atrioven-
tricular groove and posterior mitral valve leaflet on the
parasternal long-axis, apical four-chamber, or parasternal
short-axis view, using the criteria of Adler et al. (19).
All studies were recorded digitally in the DICOM format
or on super-VHS videotape and evaluated by experts in
echocardiography who were blinded to the results of coro-
nary angiography.
Peak transaortic flow velocities (average of triplicate
measurements) were measured during the TTE examina-
tion by continuous-wave Doppler imaging (20). Presence of
aortic regurgitation (21) was also noted.
Stress echocardiography. Stress echocardiography was
performed with dipyridamole (up to 0.84 mg/kg body
weight over 10 min, with atropine up to 1 mg, as needed),
dobutamine (up to 40 g/kg per min, with atropine up to
1 mg, as needed), or upright bicycle exercise, according to
standard protocol (22). Commercially available imaging
systems with digital acquisition were used. All standard
echocardiographic views were obtained when possible. The
left ventricle (LV) was divided into 16 segments, as sug-
gested by the American Society of Echocardiography (23).
Segmental wall motion was graded as follows: normal  1;
hypokinetic  2; akinetic  3; and dyskinetic  4.
Inadequately visualized segments were not scored. The
stress echocardiogram was considered positive when one LV
segment was increased by one grade or more at peak stress.
The wall motion score index was derived by dividing the
sum of individual visualized segment scores by the number
of visualized segments. Appearance of ST-segment depres-
sion1 mm at 0.08 s after the J point, as determined by the
physician, was taken as evidence of a positive stress electro-
cardiogram (ECG). Intra- and inter-observer agreement
has already been shown to be high (90%) in our laboratory
(24).
Endothelial function study. All patients were studied at
least 4 h after their last meal, according to a standard
protocol previously described in detail (25). Briefly, the
patients were instructed to lie quietly in a supine position for
10 min before the study. All studies were performed in a
temperature-controlled room (20 to 25°C). The diameter of
the brachial artery was measured from two-dimensional
ultrasound images. In each study, scans were taken at rest,
during reactive hyperemia, at rest again, and after sublingual
nitrate administration. The brachial artery was scanned in
the longitudinal section, on the dominant arm, 2 to 15 cm
above the elbow. The focus zone was set to optimize images
of the lumen–arterial wall interface, and machine-operating
parameters were not changed during the rest of the study.
The arterial diameter was measured at a fixed distance from
an anatomic marker, such as a bifurcation. Measurements
were taken from the anterior to posterior “m” line at end
Abbreviations and Acronyms
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diastole, incident with the R-wave on the ECG. Three
cardiac cycles were analyzed for each scan, and measure-
ments were averaged. Following the baseline measurements,
a pneumatic tourniquet was inflated below the elbow to a
pressure of 250 mm Hg; forearm cuff occlusion was main-
tained for 4.5 min. Sustained maximal vessel dilation and
maximal flow change occurred after 4.5 min of cuff occlu-
sion; a higher cuff occlusion time does not provide a greater
response (14). A shorter duration of cuff occlusion provides
a less intense stimulus and fails to achieve sustained vaso-
dilation 1 min after cuff release. Therefore, the arterial
diameter was measured at 1 min after cuff deflation. After
10 min of vessel recovery, rest scan and flow measurements
were repeated. Sublingual nitrate (0.3 mg glyceryl trinitrate
[Trinitrina by Pharmacia, Peapark, New Jersey]) was then
administered to evaluate endothelium-independent vasodi-
lation. The last set of scans was performed 3 min after
nitrate intake. Endothelium-dependent, post-ischemic
FMD was determined by the maximal brachial artery
diameter after exactly 60 s of reactive hyperemia, compared
with the baseline vessel diameter, and was expressed as
percent FMD. Endothelium-independent peripheral (ni-
trate medicated dilation) vasodilation is expressed as the
percent change in brachial artery diameter 3 min after
sublingual nitrate administration, using the baseline rest
diameter as a reference. Intra- and inter-observer variabili-
ties in our laboratory have been evaluated at 2.5% and 2.0%,
respectively (25).
Coronary angiography. Coronary angiography in multiple
views was performed according to the standard Judkins or
Sones technique. At least five views, including two orthog-
onal views, were acquired for the left coronary artery and at
least two orthogonal views for the right coronary artery. All
angiographic studies were performed by experienced observ-
ers who ignored the results of noninvasive stress testing.
The percent diameter stenosis was determined by quan-
titative coronary angiography, using an automated edge-
detection system (Mipron, Kontron, Germany). In our
laboratory, this method’s intra- and inter-observer variabil-
ities were 7% and 6%, respectively (26). A vessel was
considered to have significant obstruction if its diameter was
narrowed by50%, with respect to the pre-stenotic tract. A
Duke score was calculated in each patient, according to a
previously described method (27). Briefly, this prognosti-
cally validated index describes the extent and severity of
CAD using a scale from 0 to 100, from nonsignificant CAD
to severe left main coronary artery disease. It takes into
account the number of major diseased vessels and the
location and severity of stenosis.
Statistical analysis. Data were entered into Excel and
analyzed with SPSS version 10.0 (SPSS, Inc., Chicago,
Illinois). Continuous measures are expressed as the mean
value  SD. When appropriate, the 95% confidence inter-
vals (CIs) are given. Continuous variables are analyzed by
using the Student t test. Dichotomous variables are com-
pared by chi-square analysis.
Multivariate stepwise logistic regression analysis (forward
selection with likelihood ratio criterion for selection vari-
ables: 0.05 to enter; 0.10 to remove) was used to estimate
the relationship between FMD and AVS and to evaluate for
potential confounders, including age, gender, presence of
hypertension, hypercholesterolemia, diabetes mellitus, and
smoking. In all analyses, p  0.05 was considered statisti-
cally significant.
RESULTS
Sixty-six patients (64.7%) had a history of stable angina; 35
(34.3%) had a previous myocardial infarction; and 29
(28.4%) had a previous revascularization procedure (with
bypass surgery in 16 patients, angioplasty in 13 patients, and
both in 26 patients). Sixty-six patients (64.7%) were receiv-
ing anti-ischemic therapy (beta-blockers and/or calcium
antagonists) at the time of stress echocardiography and
endothelial testing.
Aortic valve sclerosis was present in 35 patients (group I)
and absent in 67 patients (group II). The characteristics of
the study groups are listed in Table 1. There were no
significant differences in baseline characteristics between the
groups.
Aortic sclerosis and valvular regurgitation. Aortic regur-
gitation was detected in 33 subjects (32.4%). Aortic regur-
gitation was trivial to mild in 19 patients (18.6%) and
moderate in 4 (3.9%). The proportion of patients with aortic
regurgitation was significantly higher among patients with
AVS (34.3%) than among patients with morphologically
normal aortic valves (16.4%; p 0.04). Mitral regurgitation
was detected in 27 patients with AVS (77.1%) and in 49
patients with morphologically normal aortic valves (73.1%;
p  NS).
Aortic sclerosis and echocardiographic parameters. End-
diastolic volume in patients with AVS was significantly
greater than that in patients with morphologically normal
aortic valves (166.4 95.9 vs. 127.6 44.9 ml, p 0.006).
The LV mass index was significantly higher in patients with
AVS than in those with no evidence of AVS (130.7  48.5
vs. 113.5 40.0 g/m2, p 0.05). There were no significant
differences in end-systolic volume, LV ejection fraction, or
wall thickness between the groups. There was also no
significant relationship between AVS and MAC. The
proportion of patients with MAC was 11.4% in patients
with AVS and 7.5% in patients without AVS (p  NS).
Aortic sclerosis and CAD. Significant CAD during cor-
onary angiography was found in 66 patients (64.7%).
Among patients with AVS, 21 had CAD (60.0%), and
among those without AVS, 45 had CAD (67.2%; p  NS).
Groups I and II had similar angiographic Duke scores
(33.8  28.3 vs. 31.7  25.8; p  NS).
Stress echocardiography. A positive result of stress echo-
cardiography was found in 17 patients (16.7%). Among
patients with AVS, eight had a positive test, and among
patients without AVS, nine had a positive result. Groups I
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and II had a similar frequency of a positive stress echocar-
diogram (22.9% vs. 13.4%; p  NS), rest wall motion score
index (1.09  0.14 vs. 1.27  0.46; p  NS), and peak
stress wall motion score index (1.19  0.23 vs. 1.30  0.45;
p  NS).
Aortic sclerosis and endothelial dysfunction. Flow-
mediated dilation was significantly lower (2.2  3.5%) in
patients with AVS than in those with morphologically
normal aortic valves (5.3  5.3%; p  0.002) (Fig. 1).
Endothelium-independent vasomotion was not statisti-
cally different between patients with AVS and those with
normal aortic valves (nitrate medicated dilation: 7.4  5.2%
vs. 9.1  6.0%; p  NS).
Multivariate analysis was performed using stepwise logis-
tic regression. Flow-mediated dilation was highly predictive
of AVS, with an odds ratio of 1.18 for each percent decrease
in FMD (95% CI 1.05 to 1.32; p 0.005). Age (p 0.95),
hypertension (p  0.23), hypercholesterolemia (p  0.76),
smoking (p  0.62), and diabetes (p  0.9) were not
predictors of AVS in this analysis.
DISCUSSION
Previous reports have noted an association between AVS
and clinical atherosclerotic cardiovascular disease (5,28). To
our knowledge, this study is the first to demonstrate an
independent association between aortic sclerosis and sys-
temic endothelial dysfunction, suggesting that these disor-
ders represent related processes in the spectrum of athero-
sclerotic cardiovascular disease.
Comparison with previous studies. Several pathologic
and echocardiographic studies (3,4,7,21) have demonstrated
a strong association between AVS and risk factors such as
age (29–32), male gender (4,33), hypertension (34), choles-
terol, diabetes, smoking (3,4), and MAC (19). Previous
studies have also shown that patients with AVS undergoing
coronary angiography have a higher prevalence of CAD
(19,35). In our study, the sample size was powered to detect
a difference in FMD, but not in the prevalence of CAD or
risk factors for CAD. The sample size is too small to expect
an association with clinical risk factors or coronary angio-
graphic findings. Previous studies have shown that AVS is
associated with an increase of 50% in the risk of cardio-




(n  67) p Value
Age (yrs) 64.6  9.1 62.9  10.0 NS
Gender (M/F) 26/9 (74.3%/25.7%) 50/17 (74.6%/25.4%) NS
Family history of CAD 15 (43%) 31 (46%) NS
Diabetes mellitus 6 (17.1%) 11 (16.4%) NS
Systemic hypertension 16 (45.7%) 37 (55.2%) NS
Hypercholesterolemia 14 (40.0%) 31 (46.3%) NS
Previous MI 10 (28.6%) 25 (37.3%) NS
CABG 3 (8.6%) 13 (19.4%) NS
PTCA 2 (5.7%) 11 (16.4%) NS
Nitrate treatment 17 (48.6%) 39 (58.2%) NS
Beta-blocker treatment 12 (34.3%) 24 (35.8%) NS
Calcium antagonist treatment 13 (37.1%) 29 (43.3%) NS
ACE inhibitor treatment 11 (31.4%) 16 (23.9%) NS
Lipid-lowering drug treatment 6 (17.1%) 16 (23.9%) NS
Smoking 16 (45.7%) 35 (52.2%) NS
Body mass index (kg/m2) 27.2  3.3 26.7  3.5 NS
Total cholesterol (mg/dl) 220.8  51.9 200.2  34.8 NS
LDL cholesterol (mg/dl) 124.4  57.8 133.1  38.9 NS
Triglycerides (mg/dl) 170.2  136.1 178.1  101.9 NS
*Patients with aortic valve sclerosis (AVS). †Subjects without AVS. Data are presented as the mean value  SD or number (%)
of patients.
ACE  angiotensin-converting enzyme; CABG  coronary artery bypass graft surgery; CAD  coronary artery disease;
LDL  low-density lipoprotein; MI  myocardial infarction; NS  not significant; PTCA  percutaneous transluminal
coronary angioplasty.
Figure 1. Endothelium-dependent flow-mediated dilation (FMD) of the
brachial artery during reactive hyperemia (endothelium-dependent vaso-
motion) is significantly higher in subjects with no evidence of aortic valve
sclerosis (AVS) than in patients with AVS. Data are expressed as the
median value (25% and 75% and outliers, in a “box-and-whiskers” plot). *p
 0.002.
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vascular death or myocardial infarction in adults 65 years
old (5).
Aronow et al. (36) reported that older patients with
valvular aortic sclerosis have a higher risk (1.8 times) of new
coronary events than older subjects without valvular aortic
sclerosis, after controlling for the confounding effects of
other prognostic variables. This supports the hypothesis that
valvular calcification is a manifestation of systemic athero-
sclerotic processes. Our data showing an association be-
tween AVS and systemic endothelial dysfunction may add
to our understanding of the relationship between aortic
sclerosis and adverse clinical outcomes in adults with CAD.
In fact, endothelial dysfunction can lead to cardiovascular
events through several mechanisms. One possible mecha-
nism is myocardial ischemia secondary to endothelial dys-
function, even in the absence of obstructive CAD (37,38).
Another possible mechanism by which coronary endothelial
dysfunction may contribute to cardiac events is through
acceleration of coronary atherosclerosis, as evidenced by the
development of obstructive CAD (39). There is also initial
evidence linking ultrasonically assessed systemic endothelial
dysfunction to a worse prognosis in patients undergoing
vascular surgery (40). The association between ultrasonically
assessed systemic endothelial dysfunction and AVS may
provide a mechanistic insight into the emerging association
between AVS and cardiovascular events.
Study limitations. The size of our study population (n 
102) may have limited our ability to detect significant, albeit
relatively less important, risk factors for AVS. We selected
patients who were scheduled to undergo coronary angiog-
raphy and stress echocardiography for a clinical indication.
These inclusion criteria might have skewed the spectrum of
the population toward more advanced forms of CAD than
studies in which mostly asymptomatic subjects were en-
rolled (3,4,34). However, these same selection criteria al-
lowed us to gain insight into multiple markers of the
atherosclerotic process, both early (such as systemic endo-
thelial dysfunction) and advanced (such as a positive stress
echocardiogram and angiographically assessed stenosis)
(41).
We did not use a digitized method to identify AVS and
MAC. This could have caused a verification bias and may
have affected the reproducibility in identifying cardiac cal-
cifications. Nevertheless, the qualitative “eyeball” method is
the one currently adopted in everyday clinical echocardio-
graphic practice.
Sixty-five percent of patients were receiving anti-ischemic
therapy at the time of testing, and it is known that this may
affect stress test sensitivity (42) and, at least for some
calcium antagonists, endothelial function. Nevertheless,
withholding of therapy in all patients would have been
impractical and/or unethical.
Conclusions. Aortic valve sclerosis is associated with sys-
temic endothelial dysfunction. This observation may pro-
vide a mechanistic insight into the emerging association
between AVS and cardiovascular events.
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